-
1
-
-
0022619110
-
Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: Results of a multicentre double-blind trial
-
Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: Results of a multicentre double-blind trial. Lancet 1986;2:119-124
-
(1986)
Lancet
, vol.2
, pp. 119-124
-
-
Feutren, G.1
Papoz, L.2
Assan, R.3
-
2
-
-
55749104546
-
Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial
-
Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 2008;372:1746-1755
-
(2008)
Lancet
, vol.372
, pp. 1746-1755
-
-
Näntö-Salonen, K.1
Kupila, A.2
Simell, S.3
-
3
-
-
0021840644
-
First degree relatives of patients with type 1 diabetes mellitus
-
Srikant S, Ganda OP, Rabizadeh A, et al. First degree relatives of patients with type 1 diabetes mellitus. N Engl J Med 1985;313:461-464
-
(1985)
N Engl J Med
, vol.313
, pp. 461-464
-
-
Srikant, S.1
Ganda, O.P.2
Rabizadeh, A.3
-
4
-
-
20544443927
-
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
-
Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608
-
(2005)
N Engl J Med
, vol.352
, pp. 2598-2608
-
-
Keymeulen, B.1
Vandemeulebroucke, E.2
Ziegler, A.G.3
-
5
-
-
1642277657
-
European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes
-
European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
-
Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-931
-
(2004)
Lancet
, vol.363
, pp. 925-931
-
-
Gale, E.A.1
Bingley, P.J.2
Emmett, C.L.3
Collier, T.4
-
6
-
-
4644230843
-
Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes
-
Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004;27:2348-2355
-
(2004)
Diabetes Care
, vol.27
, pp. 2348-2355
-
-
Harrison, L.C.1
Honeyman, M.C.2
Steele, C.E.3
-
7
-
-
79953747035
-
TRIGR Study Group. the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study: Recruitment intervention and follow-up
-
Akerblom HK, Krischer J, Virtanen SM, et al.; TRIGR Study Group. The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study: Recruitment, intervention and follow-up.Diabetologia 2011;54: 627-633
-
(2011)
Diabetologia
, vol.54
, pp. 627-633
-
-
Akerblom, H.K.1
Krischer, J.2
Virtanen, S.M.3
-
8
-
-
80053036722
-
The Environmental Determinants of Diabetes in the Young (TEDDY): Genetic criteria and international diabetes risk screening of 421 000 infants
-
TEDDY Study Group
-
Hagopian WA, Erlich H, Lernmark A, et al.; TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY): Genetic criteria and international diabetes risk screening of 421, 000 infants. Pediatr Diabetes 2011;12: 733-743
-
(2011)
Pediatr Diabetes
, vol.12
, pp. 733-743
-
-
Hagopian, W.A.1
Erlich, H.2
Et, Al.L.A.3
-
9
-
-
84879517841
-
Immune-directed therapy for type 1 diabetes at the clinical level: The Immune Tolerance Network (ITN) experience
-
Ehlers MR, Nepom GT. Immune-directed therapy for type 1 diabetes at the clinical level: The Immune Tolerance Network (ITN) experience. Rev Diabet Stud 2012;9:359-371
-
(2012)
Rev Diabet Stud
, vol.9
, pp. 359-371
-
-
Ehlers, M.R.1
Nepom, G.T.2
-
10
-
-
85012993429
-
Australasian Diabetes Data Network: BuilDing a collaborative resource
-
Australasian Diabetes Data Network (ADDN) Study Group
-
Clapin H, Phelan H, Bruns L Jr, et al.; Australasian Diabetes Data Network (ADDN) Study Group. Australasian Diabetes Data Network: BuilDing a collaborative resource. J Diabetes Sci Technol 2016;10:1015-1026
-
(2016)
J Diabetes Sci Technol
, vol.10
, pp. 1015-1026
-
-
Clapin, H.1
Phelan, H.2
Bruns, L.3
-
11
-
-
0037198427
-
Effects of insulin in relatives of patients with type 1 diabetesmellitus
-
Diabetes Prevention Trial-Type 1 Diabetes Study Group
-
Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetesmellitus. N Engl J Med 2002;346:1685-1691
-
(2002)
N Engl J Med
, vol.346
, pp. 1685-1691
-
-
-
12
-
-
18144391496
-
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1
-
Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076
-
(2005)
Diabetes Care
, vol.28
, pp. 1068-1076
-
-
Skyler, J.S.1
Krischer, J.P.2
Wolfsdorf, J.3
-
13
-
-
84939961476
-
The 6 year incidence of diabetesassociated autoantibodies in genetically at-risk children: The TEDDY study
-
TEDDY Study Group
-
Krischer JP, Lynch KF, Schatz DA, et al.; TEDDY Study Group. The 6 year incidence of diabetesassociated autoantibodies in genetically at-risk children: The TEDDY study. Diabetologia 2015; 58:980-987
-
(2015)
Diabetologia
, vol.58
, pp. 980-987
-
-
Krischer, J.P.1
Lynch, K.F.2
Schatz, D.A.3
-
14
-
-
84879114358
-
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
-
Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473-2479
-
(2013)
JAMA
, vol.309
, pp. 2473-2479
-
-
Ziegler, A.G.1
Rewers, M.2
Simell, O.3
-
15
-
-
84962406567
-
Type 1 Diabetes Trial Net Study Group. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: A Consensus Report
-
Wherrett DK, Chiang JL, Delamater AM, et al.; Type 1 Diabetes Trial Net Study Group. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: A Consensus Report. Diabetes Care 2015;38:1975-1985
-
(2015)
Diabetes Care
, vol.38
, pp. 1975-1985
-
-
Wherrett, D.K.1
Chiang, J.L.2
Delamater, A.M.3
-
16
-
-
84971282274
-
Prognostic classification factors associated with development of multiple autoantibodies, dysglycemia, and type 1 diabetesda recursive partitioning analysis
-
Type 1 Diabetes Trial Net Study Group
-
Xu P, Krischer JP; Type 1 Diabetes Trial Net Study Group. Prognostic classification factors associated with development of multiple autoantibodies, dysglycemia, and type 1 diabetesda recursive partitioning analysis. Diabetes Care 2016;39:1036-1044
-
(2016)
Diabetes Care
, vol.39
, pp. 1036-1044
-
-
Xu, P.1
Krischer, J.P.2
-
17
-
-
85036515544
-
Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: A randomized clinical trial
-
Writing Committee for the Type 1 Diabetes Trial Net Oral Insulin Study Group
-
Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ; Writing Committee for the Type 1 Diabetes Trial Net Oral Insulin Study Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: A randomized clinical trial. JAMA 2017;318: 1891-1902
-
(2017)
JAMA
, vol.318
, pp. 1891-1902
-
-
Krischer, J.P.1
Schatz, D.A.2
Bundy, B.3
Skyler, J.S.4
Greenbaum, C.J.5
-
18
-
-
84962430639
-
Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association
-
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964-1974
-
(2015)
Diabetes Care
, vol.38
, pp. 1964-1974
-
-
Insel, R.A.1
Dunne, J.L.2
Atkinson, M.A.3
-
19
-
-
0027503115
-
Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease
-
Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993;153:578-581
-
(1993)
Arch Intern Med
, vol.153
, pp. 578-581
-
-
Hebert, P.R.1
Moser, M.2
Mayer, J.3
Glynn, R.J.4
Hennekens, C.H.5
-
20
-
-
0022617990
-
Type I diabetes mellitus. A chronic autoimmune disease
-
Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360-1368
-
(1986)
N Engl J Med
, vol.314
, pp. 1360-1368
-
-
Eisenbarth, G.S.1
-
21
-
-
56649115489
-
Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1
-
Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
-
(2008)
Diabetes Care
, vol.31
, pp. 2188-2192
-
-
Sosenko, J.M.1
Palmer, J.P.2
Rafkin-Mervis, L.3
-
22
-
-
84864381301
-
Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite Type 1 Diabetes Trial Net data
-
Type 1 Diabetes Trial Net Study Group
-
Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes Trial Net Study Group. Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite Type 1 Diabetes Trial Net data. Diabetes 2012;61:2066-2073
-
(2012)
Diabetes
, vol.61
, pp. 2066-2073
-
-
Greenbaum, C.J.1
Beam, C.A.2
Boulware, D.3
-
23
-
-
84957438631
-
The implications of autoantibodies to a single islet antigen in relativeswith normal glucose tolerance: Development of other autoantibodies and progression to type 1 diabetes
-
Type 1 Diabetes Trial Net Study Group
-
Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes Trial Net Study Group. The implications of autoantibodies to a single islet antigen in relativeswith normal glucose tolerance: Development of other autoantibodies and progression to type 1 diabetes. Diabetologia 2016;59:542-549
-
(2016)
Diabetologia
, vol.59
, pp. 542-549
-
-
Bingley, P.J.1
Boulware, D.C.2
Krischer, J.P.3
-
24
-
-
85026923570
-
Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives
-
Type 1 Diabetes Trial Net Study Group
-
Bosi E, Boulware DC, Becker DJ, et al.; Type 1 Diabetes Trial Net Study Group. Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives. J Clin Endocrinol Metab 2017;102:2881-2886
-
(2017)
J Clin Endocrinol Metab
, vol.102
, pp. 2881-2886
-
-
Bosi, E.1
Boulware, D.C.2
Becker, D.J.3
-
25
-
-
84962137628
-
HLA-DRB1,15:01-DQA1,01:02-DQB1,06:02 haplotype protects autoantibody-positive relatives from type 1 diabetes throughout the stages of disease progression
-
Type 1 Diabetes Trial Net Study Group
-
Pugliese A, Boulware D, Yu L, et al.; Type 1 Diabetes Trial Net Study Group. HLA-DRB1,15:01-DQA1,01:02-DQB1,06:02 haplotype protects autoantibody-positive relatives from type 1 diabetes throughout the stages of disease progression. Diabetes 2016;65:1109-1119
-
(2016)
Diabetes
, vol.65
, pp. 1109-1119
-
-
Pugliese, A.1
Boulware, D.2
Yu, L.3
-
26
-
-
84856689949
-
Development of autoantibodies in the Trial Net Natural History Study
-
Trial Net Natural History Study Group
-
Vehik K, Beam CA, Mahon JL, et al.; Trial Net Natural History Study Group. Development of autoantibodies in the Trial Net Natural History Study. Diabetes Care 2011;34:1897-1901
-
(2011)
Diabetes Care
, vol.34
, pp. 1897-1901
-
-
Vehik, K.1
Beam, C.A.2
Mahon, J.L.3
-
27
-
-
84961223661
-
The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among Trial Net Pathway to Prevention participants
-
Type 1 Diabetes Trial Net Study Group
-
Meah FA, Di Meglio LA, Greenbaum CJ, et al.; Type 1 Diabetes Trial Net Study Group. The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among Trial Net Pathway to Prevention participants. Diabetologia 2016;59:1186-1195
-
(2016)
Diabetologia
, vol.59
, pp. 1186-1195
-
-
Meah, F.A.1
Meglio L A, D.I.2
Greenbaum, C.J.3
-
28
-
-
85026746218
-
UnderstanDing and preventing type 1 diabetes through the unique working model of Trial
-
Battaglia M, Anderson MS, Buckner JH, et al. UnderstanDing and preventing type 1 diabetes through the unique working model of Trial Net. Diabetologia 2017;60:2139-2147
-
(2017)
Net. Diabetologia
, vol.60
, pp. 2139-2147
-
-
Battaglia, M.1
Anderson, M.S.2
Buckner, J.H.3
-
29
-
-
84921742544
-
Mechanisms, impact and management of pain in rheumatoid arthritis
-
Walsh DA, Mc Williams DF. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:581-592
-
(2014)
Nat Rev Rheumatol
, vol.10
, pp. 581-592
-
-
Walsh, D.A.1
Mc Williams, D.F.2
-
30
-
-
84892408228
-
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: Overview
-
DCCT/EDIC Research Group
-
Nathan DM; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: Overview. Diabetes Care 2014;37:9-16
-
(2014)
Diabetes Care
, vol.37
, pp. 9-16
-
-
Nathan, D.M.1
-
31
-
-
84893119634
-
Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial
-
Group DER; DCCT/EDIC Research Group
-
Lachin JM, Mc Gee P, Palmer JP, Group DER; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748
-
(2014)
Diabetes
, vol.63
, pp. 739-748
-
-
Lachin, J.M.1
Mc Gee, P.2
Palmer, J.P.3
-
32
-
-
84920052627
-
Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation
-
Brooks AM, Oram R, Home P, Steen N, Shaw JA. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation. Diabetes Care 2015;38:105-112
-
(2015)
Diabetes Care
, vol.38
, pp. 105-112
-
-
Brooks, A.M.1
Oram, R.2
Home, P.3
Steen, N.4
Shaw, J.A.5
-
33
-
-
0025909735
-
Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: Lack of long-term effects
-
Martin S, Schernthaner G, Nerup J, et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: Lack of long-term effects. Diabetologia 1991;34:429-434
-
(1991)
Diabetologia
, vol.34
, pp. 429-434
-
-
Martin, S.1
Schernthaner, G.2
Nerup, J.3
-
34
-
-
0037198420
-
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
-
Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698
-
(2002)
N Engl J Med
, vol.346
, pp. 1692-1698
-
-
Herold, K.C.1
Hagopian, W.2
Auger, J.A.3
-
35
-
-
77950636402
-
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes
-
Type 1 Diabetes Trial Net MMF/DZB Study Group
-
Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al.; Type 1 Diabetes Trial Net MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010;33:826-832
-
(2010)
Diabetes Care
, vol.33
, pp. 826-832
-
-
Gottlieb, P.A.1
Quinlan, S.2
Krause-Steinrauf, H.3
-
36
-
-
84878300647
-
Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials
-
Type 1 Diabetes Trial Net Canakinumab Study Group; AIDA Study Group
-
Moran A, Bundy B, Becker DJ, et al.; Type 1 Diabetes Trial Net Canakinumab Study Group; AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381:1905-1915
-
(2013)
Lancet
, vol.381
, pp. 1905-1915
-
-
Moran, A.1
Bundy, B.2
Becker, D.J.3
-
37
-
-
79960743608
-
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial
-
Type 1 Diabetes Trial Net GAD Study Group
-
Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes Trial Net GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet 2011;378:319-327
-
(2011)
Lancet
, vol.378
, pp. 319-327
-
-
Wherrett, D.K.1
Bundy, B.2
Becker, D.J.3
-
38
-
-
70449480577
-
Rituximab B-lymphocyte depletion and preservation of beta-cell function
-
Type 1 Diabetes Trial Net Anti-CD20 Study Group
-
Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes Trial Net Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
-
(2009)
N Engl J Med
, vol.361
, pp. 2143-2152
-
-
Pescovitz, M.D.1
Greenbaum, C.J.2
Krause-Steinrauf, H.3
-
39
-
-
84893118586
-
B-lymphocyte depletion with rituximab and b-cell function: Two-year results
-
Type 1 Diabetes Trial Net Anti-CD20 Study Group
-
Pescovitz MD, Greenbaum CJ, Bundy B, et al.; Type 1 Diabetes Trial Net Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and b-cell function: Two-year results. Diabetes Care 2014; 37:453-459
-
(2014)
Diabetes Care
, vol.37
, pp. 453-459
-
-
Pescovitz, M.D.1
Greenbaum, C.J.2
Bundy, B.3
-
40
-
-
84897851090
-
Type 1 Diabetes Trial Net Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year after cessation of treatment
-
Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes Trial Net Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year after cessation of treatment. Diabetes Care 2014;37:1069-1075
-
(2014)
Diabetes Care
, vol.37
, pp. 1069-1075
-
-
Orban, T.1
Bundy, B.2
Becker, D.J.3
-
41
-
-
54049120250
-
Abatacept in the treatment of rheumatoid arthritis
-
Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther 2008;10(Suppl. 1):S5
-
(2008)
Arthritis Res Ther
, vol.10
, pp. S5
-
-
Buch, M.H.1
Vital, E.M.2
Emery, P.3
-
42
-
-
84928406046
-
Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: The Pre-POINT randomized clinical trial
-
Pre-POINT Study Group
-
Bonifacio E, Ziegler AG, Klingensmith G, et al.; Pre-POINT Study Group. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: The Pre-POINT randomized clinical trial. JAMA 2015;313:1541-1549
-
(2015)
JAMA
, vol.313
, pp. 1541-1549
-
-
Bonifacio, E.1
Ziegler, A.G.2
Klingensmith, G.3
-
43
-
-
84941874455
-
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases
-
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015;23:231-269
-
(2015)
Inflammopharmacology
, vol.23
, pp. 231-269
-
-
Rainsford, K.D.1
Parke, A.L.2
Clifford-Rashotte, M.3
Kean, W.F.4
-
44
-
-
82755162147
-
Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation
-
Michels AW, Ostrov DA, Zhang L, et al. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol 2011;187:5921-5930
-
(2011)
J Immunol
, vol.187
, pp. 5921-5930
-
-
Michels, A.W.1
Ostrov, D.A.2
Zhang, L.3
-
45
-
-
84984629801
-
Immune intervention and preservation of pancreatic beta cell function in type 1 diabetes
-
Simmons KM, Gottlieb PA, Michels AW. Immune intervention and preservation of pancreatic beta cell function in type 1 diabetes. Curr Diab Rep 2016;16:97
-
(2016)
Curr Diab Rep
, vol.16
, pp. 97
-
-
Simmons, K.M.1
Gottlieb, P.A.2
Michels, A.W.3
-
46
-
-
84887052291
-
Teplizumab (anti-CD3 m Ab) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders
-
Ab ATE Study Team
-
Herold KC, Gitelman SE, Ehlers MR, et al.; Ab ATE Study Team. Teplizumab (anti-CD3 m Ab) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766-3774
-
(2013)
Diabetes
, vol.62
, pp. 3766-3774
-
-
Herold, K.C.1
Gitelman, S.E.2
Ehlers, M.R.3
-
47
-
-
84920413163
-
Anti-thymocyte globulin/G-CSF treatment preserves b cell function in patients with established type 1 diabetes
-
Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves b cell function in patients with established type 1 diabetes. J Clin Invest 2015;125:448-455
-
(2015)
J Clin Invest
, vol.125
, pp. 448-455
-
-
Haller, M.J.1
Gitelman, S.E.2
Gottlieb, P.A.3
-
49
-
-
84973345544
-
Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: Design and initial results of the Fr1da study
-
Fr1da Study Group
-
Raab J, Haupt F, Scholz M, et al.; Fr1da Study Group. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: Design and initial results of the Fr1da study. BMJ Open 2016;6:e011144
-
(2016)
BMJ Open
, vol.6
, pp. e011144
-
-
Raab, J.1
Haupt, F.2
Scholz, M.3
-
50
-
-
84959121146
-
A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease
-
Zhao Z, Miao D, Michels A, et al. A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease. J Immunol Methods 2016;430:28-32
-
(2016)
J Immunol Methods
, vol.430
, pp. 28-32
-
-
Zhao, Z.1
Miao, D.2
Michels, A.3
-
51
-
-
85035347149
-
The influence of type 1 diabetes genetic susceptibility regions, age, sex, and family history on the progression from multiple autoantibodies to type 1 diabetes: A TEDDY study report
-
TEDDY Study Group
-
Krischer JP, Liu X, Lernmark ° A, et al.; TEDDY Study Group. The influence of type 1 diabetes genetic susceptibility regions, age, sex, and family history on the progression from multiple autoantibodies to type 1 diabetes: A TEDDY study report. Diabetes 2017;66:3122-3129
-
(2017)
Diabetes
, vol.66
, pp. 3122-3129
-
-
Krischer, J.P.1
Liu, X.2
Lernmark, A.3
-
52
-
-
55249085210
-
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes
-
Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group
-
Greenbaum CJ, Mandrup-Poulsen T, Mc Gee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
-
(2008)
Diabetes Care
, vol.31
, pp. 1966-1971
-
-
Greenbaum, C.J.1
Mandrup-Poulsen, T.2
Mc Gee, P.F.3
-
53
-
-
70350534475
-
Validity and reproducibility ofmeasurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes
-
Type 1 Diabetes Trial Net Research Group
-
Herold KC, Brooks-Worrell B, Palmer J, et al.; Type 1 Diabetes Trial Net Research Group. Validity and reproducibility ofmeasurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009;58:2588-2595
-
(2009)
Diabetes
, vol.58
, pp. 2588-2595
-
-
Herold, K.C.1
Brooks-Worrell, B.2
Palmer, J.3
-
54
-
-
84941260792
-
Heterogeneity in recent-onset type 1 diabetes-A clinical trial perspective
-
Type 1 Diabetes Trial Net Study Group
-
Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes Trial Net Study Group. Heterogeneity in recent-onset type 1 diabetes-A clinical trial perspective. Diabetes Metab Res Rev 2015;31:588-594
-
(2015)
Diabetes Metab Res Rev
, vol.31
, pp. 588-594
-
-
Bollyky, J.B.1
Xu, P.2
Butte, A.J.3
Wilson, D.M.4
Beam, C.A.5
Greenbaum, C.J.6
-
55
-
-
84988934374
-
Fall in C-peptide during first 4 years fromdiagnosis of type 1 diabetes: Variable relation to age Hb A1c and insulin dose
-
Type 1Diabetes Trial Net Study Group
-
Hao W, Gitelman S, Di Meglio LA, Boulware D, Greenbaum CJ; Type 1Diabetes Trial Net Study Group. Fall in C-peptide during first 4 years fromdiagnosis of type 1 diabetes: Variable relation to age, Hb A1c, and insulin dose. Diabetes Care 2016;39:1664-1670
-
(2016)
Diabetes Care
, vol.39
, pp. 1664-1670
-
-
Hao, W.1
Gitelman, S.2
Meglio L A, D.I.3
Boulware, D.4
Greenbaum, C.J.5
-
56
-
-
82555190963
-
Effect of rituximab on human in vivo antibody immune responses
-
Type 1 Diabetes Trial Net Study Group e5
-
Pescovitz MD, Torgerson TR, Ochs HD, et al.; Type 1 Diabetes Trial Net Study Group. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011;128: 1295-1302.e5
-
(2011)
J Allergy Clin Immunol
, vol.128
, pp. 1295-1302
-
-
Pescovitz, M.D.1
Torgerson, T.R.2
Ochs, H.D.3
-
57
-
-
84871779576
-
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab andmycophenolatemofetil
-
Type 1 Diabetes Trial Net Daclizumab/Mycophenolic Acid Study Group
-
Loechelt BJ, Boulware D, Green M, et al.; Type 1 Diabetes Trial Net Daclizumab/Mycophenolic Acid Study Group. Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab andmycophenolatemofetil. Clin Infect Dis 2013;56:248-254
-
(2013)
Clin Infect Dis
, vol.56
, pp. 248-254
-
-
Loechelt, B.J.1
Boulware, D.2
Green, M.3
-
58
-
-
85006192541
-
Screening andmonitoring for infectious complicationswhen immunosuppressive agents are studied in the treatment of autoimmune disorders
-
Type 1 Diabetes Trial Net Study Group
-
Loechelt BJ, Green M, Gottlieb PA, et al.; Type 1 Diabetes Trial Net Study Group. Screening andmonitoring for infectious complicationswhen immunosuppressive agents are studied in the treatment of autoimmune disorders. J Pediatric Infect Dis Soc 2015;4:198-204
-
(2015)
J Pediatric Infect Dis Soc
, vol.4
, pp. 198-204
-
-
Loechelt, B.J.1
Green, M.2
Gottlieb, P.A.3
-
59
-
-
84993890052
-
A model-based approach to sample size estimation in recent onset type 1 diabetes
-
Type 1 Diabetes Trial Net Study Group
-
Bundy BN, Krischer JP; Type 1 Diabetes Trial Net Study Group. A model-based approach to sample size estimation in recent onset type 1 diabetes. Diabetes Metab Res Rev 2016;32:827-834
-
(2016)
Diabetes Metab Res Rev
, vol.32
, pp. 827-834
-
-
Bundy, B.N.1
Krischer, J.P.2
-
60
-
-
80051940031
-
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes
-
Type 1 Diabetes Trial Net Anti-CD20 Study Group
-
Herold KC, Pescovitz MD, Mc Gee P, et al.; Type 1 Diabetes Trial Net Anti-CD20 Study Group. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 2011;187:1998-2005
-
(2011)
J Immunol
, vol.187
, pp. 1998-2005
-
-
Herold, K.C.1
Pescovitz, M.D.2
Mc Gee, P.3
-
61
-
-
85000502393
-
Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes
-
Haller MJ, Gitelman SE, Gottlieb PA, et al. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes 2016; 65:3765-3775
-
(2016)
Diabetes
, vol.65
, pp. 3765-3775
-
-
Haller, M.J.1
Gitelman, S.E.2
Gottlieb, P.A.3
-
63
-
-
84948765929
-
Use of dried capillary blood sampling for islet autoantibody screening in relatives: A feasibility study
-
Trial Net Study Group
-
Bingley PJ, Rafkin LE, Matheson D, et al.; Trial Net Study Group. Use of dried capillary blood sampling for islet autoantibody screening in relatives: A feasibility study. Diabetes Technol Ther 2015;17:867-871
-
(2015)
Diabetes Technol Ther
, vol.17
, pp. 867-871
-
-
Bingley, P.J.1
Rafkin, L.E.2
Matheson, D.3
-
64
-
-
85014779178
-
Use of self-collected capillary blood samples for islet autoantibody screening in relatives: A feasibility and acceptability study
-
Type 1 Diabetes Trial Net Study Group
-
Liu Y, Rafkin LE, Matheson D, et al.; Type 1 Diabetes Trial Net Study Group. Use of self-collected capillary blood samples for islet autoantibody screening in relatives: A feasibility and acceptability study. Diabet Med 2017;34:934-937
-
(2017)
Diabet Med
, vol.34
, pp. 934-937
-
-
Liu, Y.1
Rafkin, L.E.2
Matheson, D.3
-
65
-
-
85006013324
-
NIHpolicy on single-IRB reviewda new era inmulticenter studies
-
Ervin AM, Taylor HA, Ehrhardt S.NIHpolicy on single-IRB reviewda new era inmulticenter studies. N Engl J Med 2016;375:2315-2317
-
(2016)
N Engl J Med
, vol.375
, pp. 2315-2317
-
-
Ervin, A.M.1
Taylor, H.A.2
Ehrhardt, S.3
|